INTELLIA THERAPEUTICS, INC.: stockholders equity
Stockholders equity for INTELLIA THERAPEUTICS, INC. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All INTELLIA THERAPEUTICS, INC. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2014-05-06 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 671,394,000 | USD | 2026-02-26 | 10-K · 0001193125-26-076550 |
| At date | 2024-12-31 | 871,956,000 | USD | 2026-02-26 | 10-K · 0001193125-26-076550 |
| At date | 2023-12-31 | 1,050,169,000 | USD | 2026-02-26 | 10-K · 0001193125-26-076550 |
| At date | 2022-12-31 | 1,235,584,000 | USD | 2026-02-26 | 10-K · 0001193125-26-076550 |
| At date | 2021-12-31 | 1,040,244,000 | USD | 2025-02-27 | 10-K · 0000950170-25-029007 |
| At date | 2020-12-31 | 527,072,000 | USD | 2024-02-22 | 10-K · 0000950170-24-018736 |
| At date | 2019-12-31 | 269,881,000 | USD | 2023-02-23 | 10-K · 0000950170-23-004097 |
| At date | 2018-12-31 | 277,920,000 | USD | 2022-02-24 | 10-K · 0000950170-22-001981 |
| At date | 2017-12-31 | 300,597,000 | USD | 2021-02-26 | 10-K · 0001564590-21-009011 |
| At date | 2016-12-31 | 209,837,000 | USD | 2020-02-27 | 10-K · 0001564590-20-007409 |
| At date | 2015-12-31 | -21,201,000 | USD | 2019-02-27 | 10-K · 0001564590-19-004680 |
| At date | 2014-12-31 | 7,566,000 | USD | 2018-03-14 | 10-K · 0001564590-18-005544 |
| At date | 2014-05-06 | 0 | USD | 2017-03-14 | 10-K · 0001193125-17-082186 |
Related financial histories
- INTELLIA THERAPEUTICS, INC.: total assets
- INTELLIA THERAPEUTICS, INC.: total liabilities
- INTELLIA THERAPEUTICS, INC.: cash and cash equivalents
- INTELLIA THERAPEUTICS, INC.: net income or loss
- INTELLIA THERAPEUTICS, INC.: operating cash flow
- INTELLIA THERAPEUTICS, INC.: capital expenditure payments
- INTELLIA THERAPEUTICS, INC.: contract revenue excluding tax
- INTELLIA THERAPEUTICS, INC.: financing cash flow
- INTELLIA THERAPEUTICS, INC.: investing cash flow
- INTELLIA THERAPEUTICS, INC.: retained earnings or deficit
- INTELLIA THERAPEUTICS, INC.: basic weighted-average shares
- INTELLIA THERAPEUTICS, INC.: diluted weighted-average shares
- INTELLIA THERAPEUTICS, INC.: basic earnings per share
- INTELLIA THERAPEUTICS, INC.: diluted earnings per share
- INTELLIA THERAPEUTICS, INC.: income tax expense or benefit
- INTELLIA THERAPEUTICS, INC.: net property, plant and equipment
- INTELLIA THERAPEUTICS, INC.: share-based compensation expense
- INTELLIA THERAPEUTICS, INC.: operating income or loss
- INTELLIA THERAPEUTICS, INC.: current assets
- INTELLIA THERAPEUTICS, INC.: current liabilities
- INTELLIA THERAPEUTICS, INC.: current accounts payable
- INTELLIA THERAPEUTICS, INC.: net current accounts receivable
- INTELLIA THERAPEUTICS, INC.: research and development expense
Inspect the source
- Entity
- INTELLIA THERAPEUTICS, INC. / CIK 0001652130
- Captured
- 2026-09-21T17:22:52.518Z
- SEC response SHA-256
554ffcb9aec19f194819e1de5938020c2541fd6cb0f18fc951c7fec552d678be
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001652130.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))